Current Clinical Trials

A clinical trial is a research study that is done to find out if medical treatments can improve people’s health. A medical treatment can be a drug, medical device, medical procedure, or a change in a person’s behavior such as diet or exercise. People who take part in clinical trials are volunteers.  They are also called “participants.”  Clinical Trials FAQs.

Find a Clinical Trial

Therapeutic Area Condition  Study
Number
Description Status
(click on link to learn more) 
COVID-19
COVID-19 CSL312_COVID-19 A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19) Recruiting
Haematology & Thrombosis  Hemophilia A CSL627_3001 An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A Active, Not Recruiting
  Hemophilia B CSL654_3003   A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B Active, Not Recruiting
  Hemophilia A & B CSL689_2001  Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors Cancelled
  Congenital Fibrinogen Deficiency BI3023_4003   An Observational Study of the Safety and Efficacy of Fibrinogen Concentrate Human (FCH) in Subjects With Congenital Fibrinogen Deficiency  Completed
  Von Willebrand Disease CSLCT-BIO-12-83 Study of Voncento® in Subjects With Von Willebrand Disease Completed
  Reversal of acquired coagulation factor deficiency BE1116_4001 An Observational Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding Recruiting
  Sickle Cell CSL200_1001 CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Recruiting
  Sickle Cell CSL889_1001  A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease  Recruiting
Cardiovascular and Metabolic Acute Coronary Syndrome CSL112_3001 Study to investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II) Recruiting
  Renal Impairment and Acute Myocardial Infarction CSL112_2001 A Phase 2 Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction Results
  Coronary Heart Disease CSL112_1001

Assessing the pharmacokinetics, safety, and tolerability of CSL112 in healthy Japanese and Caucasian adults

Completed
  Diabetic Kidney Disease CSL346_2001 A Phase 2a Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease  Not Yet Recruiting 
Immunology and Neurology  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20_3004 Extension Study of Maintenance Treatment with Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Results
  Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro10_5004 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP (HELIPAD 1) Completed
  Dermatomyositis (DM) IgPro20_3007 A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with Dermatomyositis (DM) Recruiting
  Pediatric CIDP IgPro10_4002 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting
  Hereditary Angioedema (HAE) CSL312_2001 A study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Active, Not Recruiting
  Hereditary Angioedema (HAE) CSL830_3003

A Phase 3 study to evaluate clinical efficacy, safety, and pharmacokineti00cs of subcutaneous administration of human plasma derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema in Japanese subjects

Recruiting 
  Hidradenitis Suppurativa and Palmoplantar Pustulosis CSL324_1002 A study of the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis Active, Not Recruiting
  HIV-1  CAL-USA-11 An Adaptive Phase I/II Study of the Safety of CAL-USA-11 in HIV-1 Infected Adults Previously Exposed to ART Completed 
  Primary Immune Deficiency (PID) IgPro20_1001 Comparison of 2 Infusion Devices With Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra: An Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump Completed
  Primary Immune Deficiency (PID) IgPro20_4005 Study of Immune Deficiency Patients treated with Subcutaneous Immunoglobulin (Hizentra®) on Weekly and Biweekly Schedules Results
  Primary Immune Deficiency (PID) IgPro20_4004 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra®) in Subjects With Primary Immunodeficiency (PID) Completed
  Systemic Sclerosis IgPro10_2001 Efficacy and safety study of IgPro10 in adults with Systemic Sclerosis Active, Not Recruiting
  Systemic Sclerosis IgPro20_2001 A study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc). Recruiting
  Healthy Subjects CSL730_1001 Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults Cancelled
  Healthy Subjects CSL730_1002 A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects Not Yet Recruiting 
  Healthy Subjects CSL324_1001 Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults Completed
 Respiratory Mild Asthma CSL311_1001 A Clinical Study to test the safety, exposure, and markers of Efficacy of CSL311 in patients with mild asthma. Active, Not Recruiting
  alpha-1 antitrypsin deficiency AmAREtTI Study Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage) Recruiting
Transplant Antibody-mediated kidney transplant rejection CSL842_3001 Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients Recruiting
  Antibody-mediated kidney transplant rejection CSL300_3001 A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients Recruiting
  Acute GVHD (aGVHD) CSL964_2001 The Safety and Efficacy of Alpha 1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant Recruiting
  Graft Versus Host Disease (GVHD) CSL964_5001 A study on the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD Recruiting